1. Scrip
  2. >>Focus On Asia
  3. >>South Korea

Roivant Buoys Anti-Infective Portfolio With Novel iNtRON Asset

 
• By Jung Won Shin

Roivant Sciences has added iNtRON Biotechnology’s novel biologic candidate to its existing anti-infective portfolio in a sizable licensing deal amid recent increased global health attention on antimicrobial resistance issues but generally decreasing pharma industry interest.

Agreement business handshake partnership deal as a solution strategy with a team coming together out of tangled twisted roads on to a bridge to find a common goal.
Roivant Licenses In Novel Korean Anti-infective • Source: Shutterstock

Roivant Sciences GMBH and iNtRON Biotechnology Inc. have reached a global licensing agreement for SAL200, a novel investigational biologic under development by the South Korean biotech for the treatment of infectious diseases caused by antibiotic-resistant staphylococci, in a deal worth up to $667.5m plus sales royalties.

The hefty value of the alliance may underline a recent uptick in interest in novel antibacterials amid heightened global attention to the issue of antimicrobial resistance by health bodies including the US Centers for Disease Control (CDC), World Health Organization and others (Also see "Finance Watch: Investment In Novel Antibacterials Gets A New Boost With Qpex Launch" - Scrip, 23 October, 2018

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Korea State R&D Fund Seeks Continuity To Enable Seamless Support

 
• By Jung Won Shin

The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.

More from Focus On Asia